MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/bjd/ljag342

Медицинская библиотека · The British journal of dermatology · 2026

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.

Marzano Angelo V, Narcisi Alessandra, Tavoletti Gianluca, Rossi Luisa C, Romagnuolo Maurizio, Bianco Matteo, Amerio Paolo, Morea Edvige, Provenzano Eugenio, Rongioletti Franco, Guida Stefania, Pinto Lorenzo M, D'Amore Alessandra, Fargnoli Maria-Concetta, Pacifico Alessia, Iacovelli Paolo, Rubegni Pietro, Trovato Emanuele, Romanelli Marco, Michelucci Alessandra, Micali Giuseppe, Musumeci Maria L, Di Marco Aldo L, Napolitano Maddalena, Coronella Luigi, Foti Caterina, Borghi Alessandro, Pacetti Lucrezia, Giacalone Serena, Spigariolo Cristina B, Nazzaro Gianluca, Ribero Simone, Mastorino Luca, Belloni Fortina Anna, Sernicola Alvise, Simonetti Oriana, Matteucci Marco, Nettis Eustachio, Stingeni Luca, Pellacani Giovanni, Dattola Annunziata, Zalaudek Iris, Caposiena Caro Raffaele D, Antiga Emiliano, Baffa Maria E, Esposito Maria, Bruni Manfredo, Sena Paolo, Vezzoli Pamela, Rocca Lorenzo, Cozzani Emanuele, Gasparini Giulia, Capurro Niccolò, Savoia Paola, Calzavara-Pinton Piergiacomo, Arisi Mariachiara, Carlo Tomasini, Michelerio Andrea, Barruscotti Stefania, Picardo Mauro, Paganelli Alessia, Malagoli Piergiorgio, Pileri Alessandro, Giuffrida Roberta, Mercuri Santo R, Bianchi Vittoria G, Argenziano Giuseppe, Fulgione Elisabetta, Girolomoni Giampiero, Maurelli Martina, Costanzo Antonio, Cartocci Alessandra, Peris Ketty, Alberti-Violetti Silvia

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Vitiligo affects 0·5-2% of the global population and carries a substantial psychosocial burden. Topical ruxolitinib 1·5% cream is approved for non-segmental vitiligo based on phase-3 trial data, but real-world evidence across heterogeneous populations remains limited.

OBJECTIVES

To evaluate the real-world effectiveness, safety, and patient-reported outcomes of topical ruxolitinib across 34 Italian dermatology centres, and to identify possible clinical predictors of treatment response.

METHODS

Multicentre retrospective cohort study (July 2024-October 2025). Patients (≥12 years) with non-segmental vitiligo received ruxolitinib 1·5% cream twice daily. Primary outcomes were F-VASI75 and F-VASI90 at 24 and 52 weeks. Secondary outcomes were VNS, DLQI, VitiQoL, GAD-7, and PHQ-9.

RESULTS

860 patients (mean age 47 years; 58% female; disease duration 13·5 years; 84% previously treated) completed 24-week assessment; 229 (26·6%) had reached 52 weeks at the time of data lock. F-VASI75 was achieved by 18·5% at 24 weeks, increasing to 38·4% at 52 weeks; F-VASI90 rose from 5·7% to 25·8%. In multivariable logistic regression, summer treatment initiation (adjusted OR 6·7, 95% CI 2·7-16·8) and Koebner phenomenon (adjusted OR 1·6, 95% CI 1·04-2·66) were independent predictors of F-VASI75 at 24 weeks. At baseline, 37% of patients had moderate-to-severe anxiety (GAD-7 ≥10); this fell to 11% at 24 weeks and 2% at 52 weeks. VitiQoL, DLQI, and PHQ-9 improved at all timepoints. Adverse events were mild in 98·9%; treatment discontinuation rate was 1·5%.

CONCLUSIONS

In a large real-world population considerably more heterogeneous than registration trial cohorts, topical ruxolitinib showed progressive repigmentation through 52 weeks with excellent tolerability. Summer initiation and Koebner phenomenon independently predicted early response, findings that may inform patient counselling and the design of prospective studies. The parallel sustained reduction in anxiety and depression argues for standardised mental health assessment as a routine component of vitiligo care.

Для цитирования: Marzano Angelo V, Narcisi Alessandra, Tavoletti Gianluca, Rossi Luisa C, Romagnuolo Maurizio, Bianco Matteo, Amerio Paolo, Morea Edvige, Provenzano Eugenio, Rongioletti Franco, Guida Stefania, Pinto Lorenzo M, D'Amore Alessandra, Fargnoli Maria-Concetta, Pacifico Alessia, Iacovelli Paolo, Rubegni Pietro, Trovato Emanuele, Romanelli Marco, Michelucci Alessandra, Micali Giuseppe, Musumeci Maria L, Di Marco Aldo L, Napolitano Maddalena, Coronella Luigi, Foti Caterina, Borghi Alessandro, Pacetti Lucrezia, Giacalone Serena, Spigariolo Cristina B, Nazzaro Gianluca, Ribero Simone, Mastorino Luca, Belloni Fortina Anna, Sernicola Alvise, Simonetti Oriana, Matteucci Marco, Nettis Eustachio, Stingeni Luca, Pellacani Giovanni, Dattola Annunziata, Zalaudek Iris, Caposiena Caro Raffaele D, Antiga Emiliano, Baffa Maria E, Esposito Maria, Bruni Manfredo, Sena Paolo, Vezzoli Pamela, Rocca Lorenzo, Cozzani Emanuele, Gasparini Giulia, Capurro Niccolò, Savoia Paola, Calzavara-Pinton Piergiacomo, Arisi Mariachiara, Carlo Tomasini, Michelerio Andrea, Barruscotti Stefania, Picardo Mauro, Paganelli Alessia, Malagoli Piergiorgio, Pileri Alessandro, Giuffrida Roberta, Mercuri Santo R, Bianchi Vittoria G, Argenziano Giuseppe, Fulgione Elisabetta, Girolomoni Giampiero, Maurelli Martina, Costanzo Antonio, Cartocci Alessandra, Peris Ketty, Alberti-Violetti Silvia. Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.. The British journal of dermatology. 2026. DOI: 10.1093/bjd/ljag342.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.